Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for autoimmune, ...

Volastra Therapeutics, a clinical-stage biotechnology company pioneering first-in-class therapies targeting chromosomal ...

For patients with higher-grade or progressive IDH -mutant glioma, how do you individualize choice between radiotherapy (RT) ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering.This report tracks developments currently taking place ...

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

There are two trials that I think are probably the most excited about. One of them is called the PEAK trial, and it was a ...